European committee upholds negative opinion of Folotyn

Allos Therapeutics, developers of Folotyn (pralatrexate injection), announced some bad news from European regulators.

Allos had requested that the European Medicines Agency's Committee For Medicinal Products for Human Use (CHMP) to reconsider and re-examine its negative opinion on the company's seeking marketing authorization application (MAA) for Folotyn in Europe as a treatment for patients with peripheral T-cell lymphoma (PTCL) whose disease has progressed after at least one prior systemic therapy.

Hoping they would change their minds and therefore their opinion, Allos was disappointed to be told that after reconsideration, the CHMP merely confirmed its previous negative opinion on the drug.

"We are very disappointed with the CHMP opinion on the MAA for Folotyn in Europe," said Charles Morris, MB ChB, MRCP, chief medical officer at Allos Therapeutics. "We will continue to ... pursue regulatory approval to market Folotyn for relapsed or refractory PTCL in other countries, and to evaluate our options for bringing Folotyn to patients who could benefit from it in Europe. We also remain fully committed to advancing the Folotyn development program in hematologic malignancies, including first-line PTCL and relapsed or refractory cutaneous T-cell lymphoma."

Folotyn was given accelerated approval by the US FDA in 2009 as a single-agent for the treatment of relapsed or refractory PTCL.

Allos was recently acquired through merger by Spectrum Pharmaceuticals, makers of Zevalin, a treatment for indolent non-Hodgkin's lymphomas.

Source: MarketWatch

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap